Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “KalVista Pharmaceuticals Limited”

24 pharma patents match "KalVista Pharmaceuticals Limited" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 24
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 24 pharmaceutical patents matching "KalVista Pharmaceuticals Limited" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

24 results for “KalVista Pharmaceuticals Limited” · 30,257 patents in full index Clear search

  1. US 11739068

    Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof

    KalVista Pharmaceuticals Limited · Granted Aug 29, 2023 · Expires Aug 24, 2043

    granted
  2. US 11613527

    Enzyme inhibitors

    KalVista Pharmaceuticals Limited · Granted Mar 28, 2023 · Expires Mar 23, 2043

    granted
  3. US 11584735

    Solid forms of a plasma kallikrein inhibitor and salts thereof

    KalVista Pharmaceuticals Limited · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted
  4. US 11242333

    Inhibitors of plasma kallikrein

    KalVista Pharmaceuticals Limited · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  5. US 11234939

    Dosage forms comprising a plasma kallikrein inhibitor

    KalVista Pharmaceuticals Limited · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted
  6. US 11230537

    Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted
  7. US 11198691

    N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted
  8. US 11180484

    Pyrazole derivatives as plasma kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted
  9. US 11084809

    N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Aug 10, 2021 · Expires Aug 5, 2041

    granted
  10. US 11001578

    N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted May 11, 2021 · Expires May 6, 2041

    granted
  11. US 10781181

    N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted
  12. US 10752607

    Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  13. US 10611758

    N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  14. US 10478409

    Pharmaceutical compositions

    KalVista Pharmaceuticals Limited · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  15. US 10364238

    N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted
  16. US 10221161

    Inhibitors of plasma kallikrein

    KalVista Pharmaceuticals Limited · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted
  17. US 9849100

    Pharmaceutical compositions suitable for parenteral administration comprising aqueous suspensions of benzylamine derivatives having low solubilities

    KalVista Pharmaceuticals Limited · Granted Dec 26, 2017 · Expires Dec 21, 2037

    granted
  18. US 9834513

    Benzylamine derivatives

    KalVista Pharmaceuticals Limited · Granted Dec 5, 2017 · Expires Nov 30, 2037

    granted
  19. US 9738641

    Bicyclic inhibitors

    KalVista Pharmaceuticals Limited · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted
  20. US 9670157

    Benzylamine derivatives

    KalVista Pharmaceuticals Limited · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted
  21. US 9533987

    Heterocyclic derivates

    KalVista Pharmaceuticals Limited · Granted Jan 3, 2017 · Expires Dec 29, 2036

    granted
  22. US 9512065

    Polymorphs of N-[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride

    KalVista Pharmaceuticals Limited · Granted Dec 6, 2016 · Expires Dec 1, 2036

    granted
  23. US 9234000

    Benzylamine derivatives as inhibitors of plasma kallikrein

    KalVista Pharmaceuticals Limited · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  24. US 9051249

    Benzylamine derivatives as inhibitors of plasma kallikrein

    KalVista Pharmaceuticals Limited · Granted Jun 9, 2015 · Expires Jun 4, 2035

    granted